@article{1ccd859588ba4b1b9146aa486d2989e7,
title = "The promising evolution of targeted therapeutic strategies in cancer",
abstract = "The upcoming decade of precision medicine for cancer is moving from the translation of specific genetic findings into clinically relevant improvement to the qualitative analyses of the genomic and immune tumor microenvironment, for an integrated treatment strategy in both metastatic and early disease.",
author = "Solange Peters and Tony Mok and Antonio Passaro and J{\"a}nne, {Pasi Antero}",
note = "Funding Information: S. Peters received education grants, provided consultation, attended advisory boards, and/or provided lectures for AbbVie, Amgen, Astra-Zeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi-Sankyo, Debiop-harm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illu-mina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, PharmaMar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, and Vaccibody, from whom she has received honoraria (all fees to institution). T. Mok reports personal fees from Abbvie, Inc, ACEA Pharma, Alpha Biopharma Co. Ltd, Amgen, Amoy Diagnostics Co. Ltd., BeiGene, Berry Oncology, Boehringer Ingelheim, Blueprint Medicines Corporation, CStone Pharmaceuticals, Curio Science, Dai-ichi Sankyo, Eisai, Fishawack Facilitate Ltd., Gritstone Oncology Inc., Guardant Health, Hengrui Therapeutics, Ignyta Inc., IQVIA, Incyte Corporation, Inivata, InMed Medical Communication, Jans-sen, Lilly, Loxo-Oncology, Lunit Inc., MD Health Brazil, Medscape/ WebMD, Mirati Therapeutics Inc., MoreHealth, OrigiMed, PeerVoice, Physicians{\textquoteright} Education Resource, P. Permanyer SL, Puma Technology Inc, PrIME Oncology, Qiming Development HK Ltd., Research to Practice, Sanofi-Aventis R&D, Takeda, Touch Medical Media, Virtus Medical Group, Yuhan Corporation; grants and personal fees from AstraZeneca, Bristol-Myers Squibb, G1 Therapeutics, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche; other from geneDecode, AstraZeneca PLC, Hutchison Chi-Med, Sanomics Ltd., Aurora Tele-Oncology Ltd.; grants from Clovis Oncology, SFJ Pharmaceuticals, and grants from XCovery outside the submitted work. A. Passaro reports personal fees from AstraZeneca, Agilent/Dako, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche Genentech outside the submitted work. P.A. J{\"a}nne reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Daiichi Sankyo, Takeda Oncology; personal fees from Pfizer, Roche/Genentech, Chugai, Ignyta, LOXO Oncology, SFJ Pharma, Voronoi, Biocartis, Novartis, Sanofi, Mirati Therapeutics, Transcenta, Silicon Therapeutics, Syndax, Nuvalent, Bayer, Esai; grants from Revolution Medicines, PUMA, and grants from Astellas during the conduct of the study; in addition, P.A. J{\"a}nne is an inventor on a DFCI-owned patent for EGFR mutations issued and licensed to Lab Corp. No other disclosures were reported. Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",
year = "2021",
doi = "10.1158/2159-8290.CD-21-0124",
language = "English",
volume = "11",
pages = "810--814",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "4",
}